28
Jan

After years of setbacks for the antibiotic ceftobiprole, Basilea Pharmaceutica’s antifungal isavuconazole is now on the cusp of winning FDA approval. And Basilea thinks it and partner Astellas Pharma have a potential blockbuster on their hands.

…read more

Source: Basilea eyes blockbuster sales after antifungal gets FDA panel OK

    

0 No comments